These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

70 related articles for article (PubMed ID: 11023197)

  • 1. Antineoplastic effect of anti-erbB-2 intrabody is not correlated with scFv affinity for its target.
    Arafat W; Gómez-Navarro J; Xiang J; Siegal GP; Alvarez RD; Curiel DT
    Cancer Gene Ther; 2000 Sep; 7(9):1250-6. PubMed ID: 11023197
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Single-chain antibody-mediated gene delivery into ErbB2-positive human breast cancer cells.
    Li X; Stuckert P; Bosch I; Marks JD; Marasco WA
    Cancer Gene Ther; 2001 Aug; 8(8):555-65. PubMed ID: 11571533
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A cancer gene therapy approach utilizing an anti-erbB-2 single-chain antibody-encoding adenovirus (AD21): a phase I trial.
    Alvarez RD; Barnes MN; Gomez-Navarro J; Wang M; Strong TV; Arafat W; Arani RB; Johnson MR; Roberts BL; Siegal GP; Curiel DT
    Clin Cancer Res; 2000 Aug; 6(8):3081-7. PubMed ID: 10955787
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transductional efficacy and safety of an intraperitoneally delivered adenovirus encoding an anti-erbB-2 intracellular single-chain antibody for ovarian cancer gene therapy.
    Deshane J; Siegal GP; Wang M; Wright M; Bucy RP; Alvarez RD; Curiel DT
    Gynecol Oncol; 1997 Mar; 64(3):378-85. PubMed ID: 9062138
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effective single chain antibody (scFv) concentrations in vivo via adenoviral vector mediated expression of secretory scFv.
    Arafat WO; Gómez-Navarro J; Buchsbaum DJ; Xiang J; Wang M; Casado E; Barker SD; Mahasreshti PJ; Haisma HJ; Barnes MN; Siegal GP; Alvarez RD; Hemminki A; Nettelbeck DM; Curiel DT
    Gene Ther; 2002 Feb; 9(4):256-62. PubMed ID: 11896464
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting of bivalent anti-ErbB2 diabody antibody fragments to tumor cells is independent of the intrinsic antibody affinity.
    Nielsen UB; Adams GP; Weiner LM; Marks JD
    Cancer Res; 2000 Nov; 60(22):6434-40. PubMed ID: 11103810
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intracellular antibody against erbB-2 mediates targeted tumor cell eradication by apoptosis.
    Deshane J; Grim J; Loechel S; Siegal GP; Alvarez RD; Curiel DT
    Cancer Gene Ther; 1996; 3(2):89-98. PubMed ID: 8729907
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Making cell-permeable antibodies (Transbody) through fusion of protein transduction domains (PTD) with single chain variable fragment (scFv) antibodies: potential advantages over antibodies expressed within the intracellular environment (Intrabody).
    Heng BC; Cao T
    Med Hypotheses; 2005; 64(6):1105-8. PubMed ID: 15823695
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Inhibitory effect of endoplasmic reticulum-retained anti-type IV collagenase intrabody on invasion and proliferation of cancer cell].
    Shen EY; Wang WG; Li Y; Zhang SH; Zhen YS
    Ai Zheng; 2004 Sep; 23(9):1005-10. PubMed ID: 15363191
    [TBL] [Abstract][Full Text] [Related]  

  • 10. erbB-2 knockout employing an intracellular single-chain antibody (sFv) accomplishes specific toxicity in erbB-2-expressing lung cancer cells.
    Grim J; Deshane J; Feng M; Lieber A; Kay M; Curiel DT
    Am J Respir Cell Mol Biol; 1996 Sep; 15(3):348-54. PubMed ID: 8810638
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Inhibitory effect of anti-type IV collagenase intrabody on invasiveness of human pulmonary giant cell carcinoma PG cells in vitro].
    Shen EY; Wang WG; Zhang SH; Zhen YS
    Zhonghua Zhong Liu Za Zhi; 2006 Apr; 28(4):265-70. PubMed ID: 16875624
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cloning and characterization of anti-cathepsin L single chain variable fragment whose expression inhibits procathepsin L secretion in human melanoma cells.
    Guillaume-Rousselet N; Jean D; Frade R
    Biochem J; 2002 Oct; 367(Pt 1):219-27. PubMed ID: 12241546
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A cell surface-displayed anti-c-myc single-chain antibody: new perspectives for the genetic improvement of cellular tumor vaccines.
    de Inés C; Cochlovius B; Schmidt S; Little M
    Cancer Gene Ther; 2000 Sep; 7(9):1257-62. PubMed ID: 11023198
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reversion of transformed phenotype in ovarian cancer cells by intracellular expression of anti folate receptor antibodies.
    Figini M; Ferri R; Mezzanzanica D; Bagnoli M; Luison E; Miotti S; Canevari S
    Gene Ther; 2003 Jun; 10(12):1018-25. PubMed ID: 12776159
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rapid isolation of intrabody candidates by using an optimized non-immune phage antibody library.
    Nagano K; Imai S; Mukai Y; Nakagawa S; Abe Y; Kamada H; Tsunoda S; Tsutsumi Y
    Pharmazie; 2009 Apr; 64(4):238-41. PubMed ID: 19435141
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Selection, affinity maturation, and characterization of a human scFv antibody against CEA protein.
    Pavoni E; Flego M; Dupuis ML; Barca S; Petronzelli F; Anastasi AM; D'Alessio V; Pelliccia A; Vaccaro P; Monteriù G; Ascione A; De Santis R; Felici F; Cianfriglia M; Minenkova O
    BMC Cancer; 2006 Feb; 6():41. PubMed ID: 16504122
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bypassing tumor-specific and bispecific antibodies: triggering of antitumor immunity by expression of anti-FcgammaR scFv on cancer cell surface.
    Gruel N; Fridman WH; Teillaud JL
    Gene Ther; 2001 Nov; 8(22):1721-8. PubMed ID: 11892840
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Expression and Characterization of Single-chain Fv-Fc Fusion Protein against Human P185(erbB2)].
    Xie ZG; Guo N; Shi M; Feng JN; Yu M; Sun YX; Shen BF
    Sheng Wu Hua Xue Yu Sheng Wu Wu Li Xue Bao (Shanghai); 2003 Apr; 35(4):371-4. PubMed ID: 12673393
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intracellular expression of the anti-erbB-2 sFv N29 fails to accomplish efficient target modulation.
    Grim JE; Siegal GP; Alvarez RD; Curiel DT
    Biochem Biophys Res Commun; 1998 Sep; 250(3):699-703. PubMed ID: 9784409
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epitope mapping and structural analysis of an anti-ErbB2 antibody A21: Molecular basis for tumor inhibitory mechanism.
    Hu S; Zhu Z; Li L; Chang L; Li W; Cheng L; Teng M; Liu J
    Proteins; 2008 Feb; 70(3):938-49. PubMed ID: 17847085
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.